An initiative of Flandersbio

News

News

in het nederlands in english

Biotechstockmarket.be informs you about important stock market related life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

intro

MDxHealth Epigenetic Biomarkers Identify Men at Increased Risk of Prostate Cancer Recurrence

27.03.2017

MDxHealth SA (Euronext: MDXH.BR) today announced that results from a prospective study demonstrate that biomarkers from its ConfirmMDx® for Prostate Cancer test could help urologists monitor therapy response to improve the personalized treatment of castration resistant prostate cancer (CRPC).1 CRPC is an aggressive form of the disease that doesn't respond to traditional, hormone deprivation therapies. The study findings were presented at the 2017 European Association of Urology (EAU) Annual Congress in London, England. read more

Publication of the annual report and invitation to the annual and extraordinary shareholders' meetings

24.03.2017

Today Galapagos NV (Euronext & NASDAQ: GLPG) published its Annual Report for the financial year 2016. read more

Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017

23.03.2017

First clinical trial of CAR-T NKR-2 cell therapy completed with encouraging safety profile and unexpected signals of clinical activity at the low doses tested. Strong cash position expected to fund operations until mid-2019. read more

Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067

22.03.2017

Galapagos NV (Euronext & NASDAQ: GLPG) announces initiation of a Phase 1 study with novel potentiator GLPG3067 for cystic fibrosis (CF) in a Phase 1 study. Galapagos is to receive a $7.5 million milestone payment from its collaboration partner AbbVie for this achievement. read more

MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom

21.03.2017

MDxHealth SA (Euronext: MDXH.BR), today announced that it has signed a distribution agreement to make its SelectMDx(TM) for Prostate Cancer test available to Lab21 Clinical Laboratory's urology clients in the United Kingdom. read more

argenx announces collaboration with Broteio Pharma to develop therapeutic antibody for severe autoimmune diseases

21.03.2017

argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it has entered into a new collaboration with Broteio Pharma B.V. to develop an antibody against a novel target in the complement cascade with therapeutic potential in autoantibody- and complement-mediated indications including autoimmune haemolytic anaemia (AIHA) and antibody mediated rejection (AMR) following organ transplantation. read more

Kiadis Pharma appoints Jan Feijen as Chief Operations Officer

20.03.2017

Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces the appointment of Jan Feijen as Chief Operations Officer (COO) effective from April 1, 2017. read more

ThromboGenics NV : ThromboGenics Business Update - FY 2016

17.03.2017

- Innovative Diabetic Eye Disease Clinical and Pre-Clinical Portfolio Provides "Multiple Shots on Goal" - First Patients Enrolled in Phase II Clinical Study Evaluating THR-317 (anti-PlGF) for Diabetic Macular Edema (DME) - Cash Position - €80.1 Million at end of December 2016 read more

USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

16.03.2017

Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell-based therapies, today announced that the U.S. Patent and Trademark Office (USPTO) has decided to reject a new reexamination request of Celyad’s U.S. Patent No. 9,181,527, relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a CAR. The patent remains valid and enforceable. read more

Kiadis Pharma to present information on the design of its Phase III trial with ATIR101™ and Phase I/II trial with ATIR201™ at 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation

16.03.2017

Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that abstracts providing information on the design of the Company’s recently initiated Phase III clinical trial with lead product ATIR101™ and Phase I/II clinical trial with ATIR201™, have been accepted for poster presentation on March 27 and 28, 2017 respectively at the 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Marseille, France. read more

Bone Therapeutics Reports Full Year 2016 Results

16.03.2017

- Streamlined strategic priorities with primary focus on allogeneic pipeline - Strong progress in clinical development of allogeneic platform ALLOB® - Further demonstration of efficacy of autologous PREOB® in osteonecrosis - Cash at end of 2016: EUR 20.3 million - Management team strengthened with appointments of Thomas Lienard (CEO), Benoît Champluvier (CTMO) and Miguel Forte (CMO) read more

Biocartis receives grant for development of a fully automated MSI test

15.03.2017

Test could be validated as prognostic test for colorectal cancer and predictive test for cancer immunotherapies read more

argenx announces Annual General Meeting of Shareholders 26 April 2017

15.03.2017

argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announces that an annual general meeting of shareholders will be held on Wednesday 26 April 2017. read more

argenx reports fourth quarter business update and full year 2016 financial results

15.03.2017

Management to host conference call today at 3 pm CET / 10 am EDT read more

Genkyotex to participate in the 1st Annual H.C. Wainwright NASH Investor Conference in New York, on April 3rd, 2017

15.03.2017

Elias Papatheodorou, CEO of Genkyotex, is scheduled to present the company at 8am EST read more

Aratana Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results

14.03.2017

Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, announced its fourth quarter and full year 2016 financial results. For the quarter ended December 31, 2016, Aratana reported a net loss of $23.3 million or $0.64 diluted loss per share, which includes $10.7 million in inventory adjustments and impairment of an intangible asset. For the full year of 2016, Aratana reported a net loss of $33.6 million or $0.95 diluted loss per share, including impairment charges of intangible assets and inventory adjustments totaling $15.1 million. read more

Kiadis Pharma to present ATIR101™ Phase II trial data in Late Breaking Abstract at the International Society for Cellular Therapy (ISCT) 2017 Annual Meeting

13.03.2017

Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that data from the Company’s single dose Phase II clinical trial (NCT01794299/EudraCT 2012-004461-41) with its lead product ATIR101™ will be presented at the International Society for Cellular Therapy (ISCT) as a Late Breaking Abstract in an oral presentation at the 2017 Annual Meeting in London, UK, on May 4, 2017. read more

TiGenix Announces Top-Line Phase I/II Results of AlloCSC-01 in Acute Myocardial Infarction

13.03.2017

TiGenix NV (Euronext Brussels and Nasdaq: TIG), an advanced biopharmaceutical company focused on developing novel therapeutics from its two proprietary platforms of donor-derived expanded adipose derived stem cells (eASC) and donor-derived expanded cardiac stem cells (AlloCSCs), today announced top-line one-year results from the CAREMI clinical trial, an exploratory Phase I/II study of AlloCSCs in acute myocardial infarction (AMI). read more

Bone Therapeutics to participate in upcoming key investor conferences

10.03.2017

BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in the field of orthopaedics and bone diseases, today announces that it will participate in the following upcoming key investor conferences: read more

New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease

10.03.2017

Galapagos NV (Euronext & NASDAQ: GLPG) announces two new Phase 2 studies investigating filgotinib in small bowel Crohn's disease as well as in fistulizing Crohn's disease. These studies are being led by filgotinib collaboration partner Gilead Sciences, Inc. read more

TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial

09.03.2017

TiGenix NV (Euronext Brussels and Nasdaq: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic stem cells, today announced week 104 data from the Cx601 ADMIRE-CD study, a pivotal Phase III trial for complex perianal fistulas in Crohn's disease patients. read more

Biocartis Group NV: Study using Biocartis' liquid biopsy BRAF assay shows new option for retreatment of melanoma patients

09.03.2017

Study and editorial 'A second chance for success with BRAF and MEK inhibitors in Melanoma' published in renowned clinical journal The Lancet Oncology read more

argenx to Host Conference Call & Webcast to Report Fourth Quarter Business Update and Full Year 2016 Financial Results on March 15, 2017

09.03.2017

argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced it will host a conference call and audio webcast on Wednesday, March 15, 2017 at 3:00 pm CET (10:00 am EDT) to discuss the 2016 financial results, as well as provide a fourth quarter business update. read more

Bone Therapeutics completes recruitment of 16 patients in ALLOB® Phase I/IIA delayed-union study

09.03.2017

Last patient for interim analysis treated end of February - Results interim data analysis expected in September 2017 read more

Aratana Therapeutics to Present at Barclays Capital Global Healthcare Conference

09.03.2017

Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, plans to present at the Barclays Capital Global Healthcare Conference on Thursday, March 16, 2017 at 9:00 a.m. ET in Miami. read more

Esperite secures external financing of up to EUR 9 million to support its commercial activity and development of innovative technologies

08.03.2017

Esperite secures external financing of up to EUR 9 million to support its commercial activity and development of innovative technologies - Total investment can reach EUR 13 million upon exercise of share subscription warrants read more

Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA

08.03.2017

• IND (Investigational New Drug) approval triggers the initiation of the THINK trial in the U.S. • Rosewell Park (NY) and University of Pittsburgh Medical Center – UPMC (PA) approved and ready to enroll patients. • No toxic event in the other patients enrolled in the study so far. read more

SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic

08.03.2017

MDxHealth SA (Euronext: MDXH.BR) today announced that SelectMDx(TM) for Prostate Cancer, a non-invasive urine-based test that guides patient selection for prostate biopsy, will be used for the newly launched prostate cancer risk clinic at the University of Michigan. read more

TiGenix Receives Positive Feedback from the FDA on Cx601 Global Phase III Trial Protocol

07.03.2017

TiGenix Receives Positive Feedback from the FDA on Cx601 Global Phase III Trial Protocol read more

Ablynx’s partner, Merck KGaA, has presented new data from A Phase Ib Psoriasis study of the Bi-specific ANTI-IL-17A/F Nanobody at the annual AAD conference

06.03.2017

• All patients in the highest dose group achieved 90% skin clearance (PASI 90) compared to 0% for placebo • Skin biopsy showed complete reversal of disease pathology in the majority of patients in the high dose group • The onset of clinical effect was rapid and sustained throughout the study • Favourable safety and tolerability profile across all doses tested read more

argenx announces that Staten Biotech exercised its option to develop therapeutic SIMPLE AntibodyTM for dyslipidemia

06.03.2017

-Anti-ApoC3 antibody developed as part of research collaboration on dyslipidemia- - Represents latest collaboration to stem from the argenx's Innovative Access Program- -argenx is eligible to receive a double-digit royalty on ARGX-116 related income- read more

TiGenix Provides Update on Cx601 Marketing Authorization Application procedure in Europe

06.03.2017

TiGenix NV (Euronext Brussels and Nasdaq: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platform of allogeneic stem cells, announces that it has received the Day 180 List of Outstanding Issues (LoOI) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and expects to receive a Marketing Authorization decision for Cx601 in 2017. read more

Bone Therapeutics Strengthens Clinical Development Leadership with Appointment of Dr. Miguel Forte as Chief Medical Officer

06.03.2017

BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces the appointment of Miguel Forte, MD, PhD as Chief Medical Officer (CMO). read more

Bone Therapeutics Notice of Full Year 2016 Results - Results to be announced on Thursday 16 March 2017

03.03.2017

BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces it will release its full year results for the year ended 31 December 2016 on Thursday 16 March 2017. read more

Mithra Signs a Binding Term Sheet with the Japanese Leader in Women’s Health Fuji Pharma to Commercialize Donesta® in Japan and ASEAN[1]

02.03.2017

Mithra Pharmaceuticals, a company dedicated to Women’s Health, is pleased to announce it has signed a binding term sheet for Donesta®, its Hormonal Treatment (HT) product candidate. read more

Biocartis Group NV: Biocartis announces 2016 results, 2017 outlook and change in CEO position

02.03.2017

Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces its operational highlights and financial results for 2016, prepared in accordance with IFRS as adopted by the European Union. Furthermore, the Company today provides its outlook for 2017 and announces a change in the Company's CEO position. read more

Biocartis Group NV: Important milestone in Biocartis-Merck collaboration with launch of second liquid biopsy assay

02.03.2017

Biocartis Group NV ('Biocartis' or 'the Company'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the launch of the Idylla(TM) ctNRAS-BRAF-EGFR S492R Mutation Assay (Research Use Only or RUO). Being the third[1] liquid biopsy test for Biocartis, the newly launched assay also marks an important milestone in the partnership with the leading science and technology company Merck[2]. This collaboration is aimed at jointly developing and commercializing new liquid biopsy RAS biomarker tests for metastatic colorectal cancer (mCRC). The first assay under the collaboration, the Idylla(TM) ctKRAS Mutation Assay (RUO), was launched in December 2016. read more

MITHRA REPORTS 2016 ANNUAL RESULTS

02.03.2017

Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces its results for the year ended 31 December 2016, prepared in accordance with IFRS. read more

argenx announces intention to conduct a registered public offering in the United States

02.03.2017

argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission relating to the proposed registered public offering of its ordinary shares in the United States. The timing, number of ordinary shares and price of the proposed offering have not yet been determined. read more

TiGenix to present at Cowen's 37th Annual Health Care Conference in Boston

01.03.2017

TiGenix NV (Euronext Brussels and Nasdaq: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, today announced that Eduardo Bravo, CEO of TiGenix, will be presenting at the 37th Annual Cowen and Company's Health Care Conference in Boston (USA) at The Boston Marriott Copley Place on Monday, March 6 at 3:20-3:50PM (EST) in Regis, 3rd Floor (breakout at 4:00 PM-04:30PM (EST) at Boston University, 3rd Floor). read more

Celyad to Present at Cowen and Company 37th Annual Health Care Conference

01.03.2017

Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell-based therapies, announced that Christian Homsy, Chief Executive Officer of Celyad will present a corporate overview at the upcoming Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8th, 2017 at 9:20 a.m. ET in Boston, MA. read more

Genticel becomes “Genkyotex”: Genticel’s General Meeting approves the strategic combination with GenKyoTex SA

01.03.2017

Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a biotechnology company developing innovative immunotherapies (the “Company”), and GenKyoTex SA, a privately-held Swiss biopharmaceutical company and the leader in NOX therapies, announce that, at today’s Ordinary and Extraordinary General Meeting, Genticel’s shareholders approved the resolutions implementing the strategic combination between the two companies pursuant to the contribution agreement signed on December 22, 2016, as well as the change in the Company’s name from “Genticel” to “Genkyotex”. read more

GENTICEL announces its 2016 annual results

28.02.2017

GENTICEL (Euronext Paris and Brussels: FR0011790542) GTCL presents today its 2016 full year results in accordance with International Financial Reporting Standards (IFRS). Genticel’s 2016 Annual Financial Report including the Management Report is available on the company website (www.genticel.com - Investors/Financial information section) in French. An English version will be made available before mid-March. read more

argenx to Present at Cowen & Co 37th Annual Health Care conference

28.02.2017

argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that its Chief Executive Officer Tim Van Hauwermeiren Chief Executive Officer, will present a company overview at the Cowen & Co. 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 8:00 a.m. ET at the Boston Marriott Copley Place. read more

MITHRA AGREES EXCLUSIVE LONG-TERM LICENSE AND SUPPLY AGREEMENT WITH MAYNE PHARMA TO COMMERCIALIZE MYRING(TM) IN THE US

28.02.2017

Mithra Pharmaceuticals, a company dedicated to Women's Health, is pleased to announce an exclusive long-term license and supply agreement that extends beyond 10 years with Mayne Pharma, a leading specialty pharmaceutical company, for the commercialization in the United States of Myring(TM), Mithra's combined hormonal contraceptive vaginal ring made of ethylene vinyl acetate copolymers (EVA). Mayne Pharma is the second largest supplier of oral contraceptive products in the US market. read more

argenx announces extension of therapeutic antibody alliance with Shire

28.02.2017

argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the extension of its strategic partnership with Shire plc (NASDAQ: SHPG) to advance the discovery and development of novel human therapeutic antibodies for diverse rare and unmet diseases for a further year until May 30, 2018. read more

Galapagos doses first healthy volunteer with CF combo GLPG2222 and GLPG2451

24.02.2017

Galapagos NV (Euronext & NASDAQ: GLPG) announces dosing of the first healthy volunteer with a combination of novel corrector GLPG2222 and novel potentiator GLPG2451 for cystic fibrosis in a Phase 1 study. read more

Galapagos reports strong financial results and newsflow-rich pipeline

24.02.2017

Galapagos NV (Euronext & NASDAQ: GLPG) presents financial results and highlights the key events for the full year 2016. read more

MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy

23.02.2017

MDxHealth SA (Euronext: MDXH.BR), today announced that it has signed a distribution agreement to make its SelectMDx(TM) for Prostate Cancer test available to Istituto Diagnostico Varelli's urology clients throughout central-south Italy. read more

Ablynx announces 2016 full year results

23.02.2017

Significant progress in key pre-clinical and clinical development programmes read more

MDxHealth Reports Financial Year 2016 Results

23.02.2017

Record revenue of $30 million, up 70% from 2015 - Total test volume up 57% over 2015. Conference call for analysts and investors today at 15:00 CET / 09:00 EST, details below read more

Takeda and TiGenix Report New Data Highlighting Maintenance of Long-Term Remission of Complex Perianal Fistulas in Crohn's Disease Patients with Cx601

17.02.2017

Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") and TiGenix NV (Euronext Brussels and Nasdaq: TIG) ("TiGenix") today announced new data from the Phase 3 ADMIRE-CD clinical trial, which indicated that investigational compound Cx601, a suspension of allogeneic adipose-derived stem cells (eASC), maintained long-term remission of treatment refractory complex perianal fistulas in patients with Crohn's disease over 52 weeks.[1] Results were presented at the 12th Congress of the European Crohn's and Colitis Organisation (ECCO). read more

GENTICEL Updates Its Financial Calendar For 2017

17.02.2017

GENTICEL (Euronext Paris and Brussels: FR0011790542 - GTCL), a French biotechnology company today announces that the disclosure of its 2016 Annual Results is moved from the 16 March 2017 to the 28 February 2017, including the publication of its 2016 Financial Report. read more

Celyad Registers First Hematological Patient in CAR-T NKR-2 THINK Trial

17.02.2017

Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell-based therapies, today announced a further step in the CAR-T NKR-2 THINK trial with the registration of a first refractory Multiple Myeloma patient. This patient is expected to receive the first dose-level (3x108 CAR-T NKR-2 cells) in the coming weeks, opening the first cohort of the hematological arm of the study. read more

Celyad Registers First Hematological Patient in CAR-T NKR-2 THINK Trial

16.02.2017

Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell-based therapies, today announced a further step in the CAR-T NKR-2 THINK trial with the registration of a first refractory Multiple Myeloma patient. This patient is expected to receive the first dose-level (3x108 CAR-T NKR-2 cells) in the coming weeks, opening the first cohort of the hematological arm of the study. read more

ABLYNX WILL ANNOUNCE ITS 2016 FULL YEAR RESULTS WITH WEBCAST ON 23 FEBRUARY 2017

16.02.2017

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] will announce its full year results for 2016 on Thursday 23 February 2017 at 7.00 am CET. read more

Mithra Granted EUR 1.9 million in Non-Dilutive Funding

13.02.2017

Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that it has been granted EUR 1.9 million in non-dilutive funding1 from the Walloon Region. The grant follows a decision by the VicePresident and Minister for Economy, Industry, Innovation and New Technologies, Mr Jean-Claude Marcourt. read more

MDxHealth Notice of Financial Year 2016 Results

09.02.2017

MDxHealth SA (Euronext: MDXH.BR) or the "Company" today announced that it will release its full year results for the financial year ended 31 December 2016 on Thursday 23 February 2017. read more

argenx to Present at Leerink Partners 6th Annual Global Healthcare Conference

09.02.2017

argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that its Chief Executive Officer Tim Van Hauwermeiren will present at the Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15, 2017 at 1:30 p.m. ET in New York City. read more

ABLYNX TO PRESENT ADDITIONAL DATA FOR ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, A POTENTIAL BEST-IN-CLASS TREATMENT FOR RHEUMATOID ARTHRITIS

09.02.2017

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] announced that today it will present additional data from the Phase IIb RA combination study of its anti-IL-6R Nanobody®, vobarilizumab, at the Annual Scientific Meeting of the Canadian Rheumatology Association, being held from 8-11 February 2017 in Ottawa, Ontario (Canada). These data will be presented in two posters which will be available on the Ablynx website shortly after the conference. read more

MDxHealth Awarded US Department of Veterans Affairs Contract for ConfirmMDx Testing

08.02.2017

MDxHealth SA (Euronext: MDXH.BR) today announced that it has been awarded a US Government Services Administration (GSA) supply contract to use ConfirmMDx for Prostate Cancer within the Department of Veterans Affairs (VA). read more

MITHRA COMPLETES RECRUITMENT FOR EUROPEAN PHASE III ESTELLE® STUDY

07.02.2017

Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that it has completed recruitment into the Phase III study of its product candidate Estelle®, a combined oral contraceptive based on Estetrol (E4) and Drospirenone (DRSP), in Europe and Russia. read more

TiGenix announces acceptance of Cx601 abstract for oral presentation at 12th Congress of ECCO

06.02.2017

TiGenix NV (Euronext Brussels and Nasdaq: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, today announced that the abstract related to the positive results of the ADMIRE-CD pivotal Phase III trial of Cx601 for complex perianal fistulas in Crohn's disease patients after 52 weeks has been accepted for oral presentation at the upcoming 12th Annual Congress of the European Crohn's and Colitis Organization (ECCO). read more

ABLYNX SUBMITS A MARKETING AUTHORISATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR CAPLACIZUMAB, ITS ANTI-vWF NANOBODY, FOR THE TREATMENT OF aTTP

06.02.2017

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for approval of caplacizumab, its first-in-class anti-von Willebrand factor (vWF) Nanobody® for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP), an ultra-rare, acute, life-threatening blood clotting disorder with a high unmet medical need. read more

Galapagos doses first patient with novel CF corrector GLPG2222

02.02.2017

Galapagos NV (Euronext & NASDAQ: GLPG) announces dosing of the first patient with cystic fibrosis (CF) Class III (F508del and a gating mutation like G551D) with novel CF corrector GLPG2222 as an add-on to Kalydeco®[1] in a Phase 2a study. Galapagos further announced the opening of an Investigational New Drug (IND) file with the US Food & Drug Administration for GLPG2222, triggering a $10 million milestone payment. read more

Registration of Document E pertaining to the planned strategic combination between Genticel and Genkyotex

01.02.2017

Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a biotechnology company developing innovative immunotherapies, and Genkyotex, a privately-held Swiss biopharmaceutical company and the leader in NOX therapies, today announce that the information document (Document E) drawn up in relation to the planned strategic combination between the two companies announced on December 22, 2016 was registered with the French financial market authority (Autorité des Marchés Financiers - AMF) under reference number E.17-004 on January 31, 2017. read more

TiGenix Enrolls First Patient in Phase Ib/IIa Clinical Trial of Cx611 in Severe Sepsis

31.01.2017

TiGenix NV (Euronext Brussels and Nasdaq: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, today announced that the first patient has been enrolled and treated in its Phase Ib/IIa clinical trial for Cx611 (SEPCELL) in the treatment of severe sepsis in community-acquired pneumonia (CAP). read more

Mithra Strengthens Position in the Belgian Contraception Market

31.01.2017

Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that it increased its market share in Belgium by 0.97% to 45.84% compared to 2015, placing it ahead of Bayer and Merck. The Company also achieved an increase in sales of 4.23%. read more

Genticel: business update for the fourth quarter 2016

31.01.2017

Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology, today announced its cash & cash equivalents and liquid investments position and its highlights from the fourth quarter of 2016. read more

Ablynx’s partner, Merck KGaA, reports encouraging results with the Bi-specific nanobody ANTIL-IL-17A/F (M1095) in A phase In clinical study in patients with psoriaris

26.01.2017

• Primary objective of safety and tolerability met • In the three highest dose groups, 100% of patients achieved a 75% or greater reduction in disease activity compared to 0% for placebo • The onset of clinical effect was rapid and sustained throughout the study read more

Genticel announces its financial calendar for 2017

26.01.2017

GENTICEL (Euronext Paris and Brussels: FR0011790542 - GTCL), a French biotechnology company today announces its schedule for the publication of financial information in 2017 and the date of its 2017 Annual General Meeting. read more

MITHRA PLANS TO SUBMIT MYRING FOR US AND EU APPROVAL IN Q2 2017

24.01.2017

Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that it intends to submit its combined hormonal contraceptive vaginal ring, Myring, for marketing approval in both Europe and the United States in Q2 2017. read more

VAN HERK INVESTMENTS B.V. ANNOUNCES 10.07% SHAREHOLDING IN ABLYNX

24.01.2017

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Van Herk Investments B.V. read more

Galapagos creates new warrant plan

23.01.2017

Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 150,000 warrants under a new warrant plan for the benefit of an employee of a subsidiary of the Company. read more

Mithra Announces US Patent Allowance for the Use of Estetrol as Emergency Contraceptive

18.01.2017

Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 14/238,310 a patent which covers the use of Estetrol (E4) as an emergency contraceptive. read more

Ablynx Announces Warrant Excercise

18.01.2017

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 154,342 common shares have been issued by the Company in exchange for €1,011,939.05 as the result of the exercise of warrants. read more

MDxHealth Announces Horizon Blue Cross Blue Shield of New Jersey Issues Positive Coverage Policy on ConfirmMDx

18.01.2017

MDxHealth SA (Euronext: MDXH.BR) today announced that Horizon Blue Cross Blue Shield (Horizon BCBS) of New Jersey has issued a positive medical policy for the ConfirmMDx® for Prostate Cancer test. read more

Dr. Walid Abi-Saab joins Galapagos as Chief Medical Officer

18.01.2017

Galapagos NV (Euronext & NASDAQ: GLPG) announces the appointment of Dr. Walid Abi-Saab to the role of Chief Medical Officer, beginning on 1 March 2017. read more

Bone Therapeutics Provides Business Update for Q4 2016

17.01.2017

BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in the field of orthopaedics and bone diseases, today provides a business update for the fourth quarter ended 31 December 2016. read more

MITHRA’S NORTH AMERICAN ADVISORY BOARD FOR DONESTA® WILL MEET IN MIAMI, FLORIDA 20TH - 21ST JANUARY 2017

12.01.2017

In order to support the development programme and to prepare its product candidate for a future introduction on the market, Mithra has set up a North American advisory committee. Composed of 7 acknowledged menopause experts from the USA and Canada, this committee will especially advise Mithra on the clinical relevance and the potential added value of E4 based product candidate for the treatment of vasomotor symptoms. The committee will work with Mithra to challenge the current and future development plan with the needs of the community at large. read more

Celyad Announces Registration of the First Pancreatic Cancer Patient in its CAR-T NKR-2THINK Trial in Belgium

12.01.2017

Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell-based therapies, today announced the activation of a second clinical site in Belgium for the THINK trial, with the registration of a pancreatic cancer patient at Cliniques Universitaires Saint-Luc (UCL). read more

MITHRA ANNOUNCES 2017 FINANCIAL CALENDAR

12.01.2017

Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces its financial calendar for 2017. read more

ABLYNX INITIATES THE PHASE IIb "RESPIRE" STUDY OF ITS WHOLLY-OWNED, FIRST-IN-CLASS, INHALED ANTI-RSV NANOBODY, ALX-0171, FOR THE TREATMENT OF RSV INFECTIONS IN HOSPITALISED INFANTS

12.01.2017

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has dosed the first patient in the Phase IIb "RESPIRE" dose-ranging efficacy study of ALX-0171, its novel inhaled drug candidate to treat RSV infections. Topline results from this Phase IIb study of inhaled ALX-0171 are expected in the second half of 2018. read more

ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (anti-PlGF) for Diabetic Macular Edema (DME)

10.01.2017

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company, focused on developing novel medicines for diabetic eye disease, announces the enrollment of the first patients in a Phase II, single-masked, multicenter exploratory study evaluating the safety and efficacy of 2 dose levels of THR-317 for the treatment of diabetic macular edema (DME). read more

Publication of a Transparency Notification Received by Mithra Pharmaceuticals SA/NV

10.01.2017

Regulated information – In accordance with article 14 of the Law of 2 May 2007 on the disclosure of large shareholdings, Mithra Pharmaceuticals SA/NV publishes the following information: read more

argenx launches Phase II proof-of-concept study of ARGX-113 for the treatment of myasthenia gravis

09.01.2017

argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced the initiation of a Phase II proof-of-concept study of ARGX-113 in patients with myasthenia gravis (MG). read more

Takeda notifies 4.48% shareholding in TiGenix

09.01.2017

TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") publishes today a transparency notification pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions. read more

Celyad Announces USPTO Decision to Uphold US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

09.01.2017

Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell-based therapies, announced today that the U.S. Patent and Trade Office (USPTO) has decided to uphold Celyad’s U.S. Patent No. 9,181,527, relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a CAR. read more

MDxHealth Announces Preliminary Update on 2016 Results and Appointment of CFO

09.01.2017

MDxHealth SA (Euronext: MDXH.BR) today provides a preliminary update on its year-end results, reporting that it expects to achieve its upgraded market guidance for full-year 2016 financial results following continued strong growth of ConfirmMDx® and early adoption of SelectMDx(TM) for Prostate Cancer during the year. read more

APPOINTMENT OF CHRISTOPHE MARÉCHAL AS CHIEF FINANCIAL OFFICER

09.01.2017

Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces the appointment of Christophe Maréchal as Chief Financial Officer (CFO) with effect from 23 February 2017. read more

Bone Therapeutics Granted EUR 2.3 Million in Non-Dilutive Funding by the Walloon Region

06.01.2017

BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention, today announces it has been granted EUR 2.3 million in non-dilutive funding* to support its research programs. This funding has been granted by the Walloon Region by decision of the Minister for Economy, Industry, Innovation and New Technologies, Mr Jean-Claude Marcourt. read more

Ablynx to present at the 35th annual J.P. Morgan Healthcare Conference

05.01.2017

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] will present at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday 11 January 2017 at 4:30 p.m. Pacific Standard Time (1.30 a.m. on Thursday 12 January, Central European Time). read more

Celyad Announces Registration of the first patient in the Belgian THINK trial

05.01.2017

• A first colorectal cancer patient has been registered at Institut Jules Bordet. • CAR-T NKR-2 processing started yesterday at Celyad’s manufacturing facility, in Mont-Saint-Guibert. read more

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

02.01.2017

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from FMR LLC. read more

Genticel and Genkyotex Announce Intention to Enter into Strategic Combination

23.12.2016

Genkyotex is a pioneer in discovery and development of NOX therapeutics read more

TiGenix Submits Day 120 Responses to European Medicines Agency for Cx601 Marketing Authorization

23.12.2016

TiGenix NV (Euronext Brussels and Nasdaq: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, today announced that it has submitted its responses to the European Medicines Agency's (EMA) Day 120 List of Questions for Cx601, its lead product candidate being developed for the treatment of complex perianal fistulas in patients with Crohn's disease. read more

FMR LLC ANNOUNCE 9.16% SHAREHOLDING IN ABLYNX

23.12.2016

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from FMR LLC. read more

ThromboGenics NV : ThromboGenics Announces Protocol Amendment to Phase II CIRCLE Trial Evaluating THR-409 (ocriplasmin) in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)

23.12.2016

ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company developing novel medicines for back of the eye disease, with a focus on diabetic eye disease, today announced that the protocol of the Phase II CIRCLE Trial Evaluating Multiple Doses of THR-409 to induce a Total Posterior Vitreous Detachment in Patients with Non-Proliferative Diabetic Retinopathy (NPDR) has been amended. read more

Mithra Launches its Product Tibelia on the Global Market

22.12.2016

Mithra Pharmaceuticals, a company focused on Women’s Health, announces today that it obtained 14 Marketing Authorizations for the commercialization of its product Tibelia in the United Kingdom, Belgium, Holland, Luxembourg, Spain, Portugal, Germany, Hungary, Poland, Norway, Sweden and Finland. Mithra is still waiting for 3 MA in France, Greece and Italy that should be received by the beginning of 2017. The product based on tibolone developed by Mithra will be more competitive due to its extended shelf-life. read more

Biocartis Group NV: Biocartis and Amgen sign a RAS Biomarker Testing Collaboration in Europe

22.12.2016

Biocartis Group NV ('Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced the signing of a new collaboration agreement with Amgen, a leading biotechnology company. The new agreement, which builds on the existing collaboration between both companies announced on 3 February 2016[1], aims at accelerating access to RAS biomarker information in up to 10 European countries. read more

Back to top

Print